Evidence map›Paper›PMID 23907540›Full record

ArticleOncotarget2013

PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1.

Alexander Gont, Jennifer E L Hanson, Sylvie J Lavictoire, Doris A Parolin, Manijeh Daneshmand, Ian J Restall, Mathieu Soucie, Garth Nicholas, John Woulfe, Amin Kassam and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Oncotarget, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Frontiers in genetics · 2019
    Review
  6. Article
  7. Engineering PTEN-L for Cell-Mediated Delivery.Molecular therapy. Methods & clinical development · 2018
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Hyaluronan expression in primary and secondary brain tumors.Annals of translational medicine · 2015
    Article
  15. Article
  16. Ephs and Ephrins in malignant gliomas.Growth factors (Chur, Switzerland) · 2014
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Alexander GontCentre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, K1H 8L6, Canada.
Jennifer E L Hanson
Sylvie J Lavictoire
Doris A Parolin
Manijeh Daneshmand
Ian J Restall
Mathieu Soucie
Garth Nicholas
John Woulfe
Amin Kassam
Vasco F Da Silva
Ian A J Lorimer
University of Ottawa · CAOttawa Hospital Research InstituteOttawa Hospital · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

Glioblastoma multiforme is an aggressive and incurable type of brain tumor. A subset of undifferentiated glioblastoma cells, known as glioblastoma tumor initiating cells (GTICs), has an essential role in the malignancy of this disease and also appears to mediate resistance to radiation therapy and chemotherapy. GTICs retain the ability to differentiate into cells with reduced malignant potential, but the signaling pathways controlling differentiation are not fully understood at this time. PTEN loss is a very common in glioblastoma multiforme and leads to aberrant activation of the phosphoinositide 3-kinase pathway. Increased signalling through this pathway leads to activation of multiple protein kinases, including atypical protein kinase C. In Drosophila, active atypical protein kinase C has been shown to promote the self-renewal of neuroblasts, inhibiting their differentiation along a neuronal lineage. This effect is mediated by atypical protein kinase c-mediated phosphorylation and inactivation of Lgl, a protein that was first characterized as a tumour suppressor in Drosophila. The effects of the atypical protein kinase C/Lgl pathway on the differentiation status of GTICs, and its potential link to PTEN loss, have not been assessed previously. Here we show that PTEN loss leads to the phosphorylation and inactivation of Lgl by atypical protein kinase C in glioblastoma cells. Re-expression of PTEN in GTICs promoted their differentiation along a neuronal lineage. This effect was also seen when atypical protein kinase C was knocked down using RNA interference, and when a non-phosphorylatable, constitutively active form of Lgl was expressed in GTICs. Thus PTEN loss, acting via atypical protein kinase C activation and Lgl inactivation, helps to maintain GTICs in an undifferentiated state.

Indexed as

AnimalsBrain NeoplasmsCell DifferentiationCytoskeletal ProteinsGlioblastomaHeterograftsHumansMiceMice, SCIDPhosphorylationProtein Kinase CPTEN PhosphohydrolaseRNA InterferenceSignal TransductionTransfectionCytoskeletal ProteinsLLGL1 protein, humanProtein Kinase CPTEN PhosphohydrolasePTEN protein, human

Identifiers

PMID23907540
PMCPMC3787156
OpenAlexW1525607149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.